相似文献
1
NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies.
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9184-9. doi: 10.1073/pnas.1105398108. Epub 2011 May 16.
2
Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.
Blood. 2020 Jan 16;135(3):167-180. doi: 10.1182/blood.2019002045.
3
An NF-κB-microRNA regulatory network tunes macrophage inflammatory responses.
Nat Commun. 2017 Oct 11;8(1):851. doi: 10.1038/s41467-017-00972-z.
4
Ablation of miR-146b in mice causes hematopoietic malignancy.
Blood Adv. 2018 Dec 11;2(23):3483-3491. doi: 10.1182/bloodadvances.2018017954.
5
MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1.
Oncotarget. 2015 May 10;6(13):11023-37. doi: 10.18632/oncotarget.3433.
6
Apolipoprotein E enhances microRNA-146a in monocytes and macrophages to suppress nuclear factor-κB-driven inflammation and atherosclerosis.
Circ Res. 2015 Jun 19;117(1):e1-e11. doi: 10.1161/CIRCRESAHA.117.305844. Epub 2015 Apr 22.
7
MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice.
Elife. 2013 May 21;2:e00537. doi: 10.7554/eLife.00537.
8
microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer.
Mol Cancer. 2012 Sep 20;11:71. doi: 10.1186/1476-4598-11-71.
9
Myeloid cells control termination of lung inflammation through the NF-kappaB pathway.
Am J Physiol Lung Cell Mol Physiol. 2009 Mar;296(3):L320-7. doi: 10.1152/ajplung.90485.2008. Epub 2008 Dec 19.
10
Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-κB-dependent manner.
Cell Stem Cell. 2014 Jul 3;15(1):51-65. doi: 10.1016/j.stem.2014.04.021.
引用本文的文献
1
Inflammatory signaling in the pathogenesis of acute myeloid leukemia.
Hemasphere. 2025 Aug 13;9(8):e70188. doi: 10.1002/hem3.70188. eCollection 2025 Aug.
2
A Multimodal Therapeutic Strategy for Inflammatory Bowel Disease Using MicroRNA-146a Mimic Encapsulated in Lipid Nanoparticles.
Mol Pharm. 2025 Jun 2;22(6):3132-3141. doi: 10.1021/acs.molpharmaceut.5c00014. Epub 2025 May 5.
3
Mechanisms underlying TRPV4-mediated regulation of miR-146a expression.
Front Immunol. 2024 Sep 30;15:1437540. doi: 10.3389/fimmu.2024.1437540. eCollection 2024.
4
Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis.
Front Mol Biosci. 2024 Sep 10;11:1388476. doi: 10.3389/fmolb.2024.1388476. eCollection 2024.
5
MicroRNA dysregulation in myelodysplastic syndromes: implications for diagnosis, prognosis, and therapeutic response.
Front Oncol. 2024 Aug 2;14:1410656. doi: 10.3389/fonc.2024.1410656. eCollection 2024.
6
Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML.
iScience. 2024 Apr 24;27(6):109809. doi: 10.1016/j.isci.2024.109809. eCollection 2024 Jun 21.
7
CLPs-miR-103a-2-5p inhibits proliferation and promotes cell apoptosis in AML cells by targeting LILRB3 and Nrf2/HO-1 axis, regulating CD8 + T cell response.
J Transl Med. 2024 Mar 14;22(1):278. doi: 10.1186/s12967-024-05070-5.
8
In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms.
Blood. 2024 Jun 6;143(23):2414-2424. doi: 10.1182/blood.2023022804.
9
MiRNA-146a-A Key Player in Immunity and Diseases.
Int J Mol Sci. 2023 Aug 14;24(16):12767. doi: 10.3390/ijms241612767.
10
Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation.
Haematologica. 2023 Oct 1;108(10):2715-2729. doi: 10.3324/haematol.2022.282349.
本文引用的文献
1
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice.
J Exp Med. 2011 Jun 6;208(6):1189-201. doi: 10.1084/jem.20101823. Epub 2011 May 9.
2
Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses.
Cell. 2010 Sep 17;142(6):914-29. doi: 10.1016/j.cell.2010.08.012.
3
MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1.
Immunity. 2010 Jul 23;33(1):48-59. doi: 10.1016/j.immuni.2010.06.013. Epub 2010 Jul 1.
4
Immunity, inflammation, and cancer.
Cell. 2010 Mar 19;140(6):883-99. doi: 10.1016/j.cell.2010.01.025.
5
Physiological and pathological roles for microRNAs in the immune system.
Nat Rev Immunol. 2010 Feb;10(2):111-22. doi: 10.1038/nri2708.
6
Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.
Nat Med. 2010 Jan;16(1):49-58. doi: 10.1038/nm.2054. Epub 2009 Nov 8.
7
MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2.
J Immunol. 2009 Aug 1;183(3):2150-8. doi: 10.4049/jimmunol.0900707. Epub 2009 Jul 13.
8
NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy.
Apoptosis. 2009 Apr;14(4):348-63. doi: 10.1007/s10495-009-0315-0.
9
MicroRNAs: target recognition and regulatory functions.
Cell. 2009 Jan 23;136(2):215-33. doi: 10.1016/j.cell.2009.01.002.
10
MicroRNA control in the immune system: basic principles.
Cell. 2009 Jan 9;136(1):26-36. doi: 10.1016/j.cell.2008.12.027.
Zotero 插件